Innovent Biologics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- De-Chao Yu
- Full Time Employees
- 5,659
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 168 Dongping Street Suzhou People's Republic of China 215123
- IPO Date
- Sep 4, 2019
- Website
- innoventbio.com
- Similar Companies
- Business
- Innovent Biologics, Inc. (IVBXF) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes high-quality monoclonal antibodies and other biologics for oncology, ophthalmology, autoimmune, cardiovascular, metabolic, and other major diseases. Founded in 2011 and headquartered in Suzhou, China, the company offers marketed products including Tyvyt (sintilimab), a human anti-PD-1 monoclonal antibody; BYVASDA (bevacizumab), a fully-human anti-VEGF monoclonal antibody; HALPRYZA (rituximab), a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO (adalimumab), a fully-human anti-TNF-α monoclonal antibody; Pemazyre (pemigatinib), a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor; Cyramza (ramucirumab), a VEGF receptor 2 antagonist; and Retsevmo (selpercatinib), a selective RET kinase inhibitor; with 17 products launched overall and a pipeline featuring IBI-128 (non-purine xanthine oxidase inhibitor), IBI-353 (PDE4 inhibitor), IBI-311 (anti-IGF-1R monoclonal antibody), and others in Phase 3 or early clinical stages. Innovent operates primarily in the People's Republic of China, with activities in the United States and Indonesia, partnering with over 30 global healthcare companies such as Eli Lilly, Roche, Sanofi, Incyte, and LG Chem; it also distributes pharmaceutical products and provides research, development, and consultation services. Recent developments include the closing in December 2025 of a global strategic partnership with Takeda, announced in October 2025, under which Takeda pays Innovent an upfront $1.2 billion including a $100 million equity investment to advance next-generation IO backbone therapies and ADC molecules like IBI363 for global development and commercialization outside China.
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable S
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies
Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 88.4% in February
Innovent Biologics Strikes Partnership Deal With Eli Lilly
China's Innovent clinches new Lilly deal for immunology, cancer drug development
Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat